Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
P 1 (1)

Trial Status

Active Not Recruiting1
Not Yet Recruiting1
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07292961Not ApplicableRecruiting

Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma

NCT06400303Phase 1Active Not Recruiting

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

NCT06871644Not ApplicableNot Yet RecruitingPrimary

Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases

Showing all 3 trials

Research Network

Activity Timeline